Consequences of steroid therapy on the adaptive immune system

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00004711

Enrollment

100

Registered

2014-02-26

Start date

2012-05-30

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M31.6 M35.3 M31.5

Interventions

Group 1: Effects of steroid therapy on the homoeostasis of the specific cellular immunesystem and the homoral immunity in patients with RZA and PMR. After informed consent 8ml EDTA blood and 8ml serum

Eligibility

Sex/Gender

All

Age

50 Years to 90 Years

Inclusion criteria

Inclusion criteria: arm 1: adult RZA or PMR patient under or up to 2 months after steroid therapy arm 2: adult patients with cataract before surgery under or up to 2 months after steroid therapy, matched for age and sex

Exclusion criteria

Exclusion criteria: - patients with existing immune defects as antibody deficiency or severe cytopenia - further immune suppressive therapies apart from MTX, especially after Rituximab therapy - previous or current chemotherapy - further reumathic basic diseases - malignoma, especially lymphoma arm 2: in addition: steroid therapy und/or MTX therapy currently or in the previous 2 months

Design outcomes

Primary

Measure	Time frame
Serum immunoglobulins, peripheral T and B cell populations under long time steroid therapy measured with nephelometry and flow cytometry	—

Secondary

Measure	Time frame
association of changes within B and T cell population with the occurence of hypogammaglobulinaemia under steroid therapy	—

Countries

Germany

Contacts

Public ContactKlaus Warnatz

Universitätsklinikum Freiburg Centrum für Chronische Immundefizienz, CCI

klaus.warnatz@uniklinik-freiburg.de0761 270 71000

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026